Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics reported a FY EPS of $(1.14), surpassing the $(1.28) estimate, marking a 12.98% improvement from last year's $(1.31) per share loss. As of December 31, 2023, the company has $23.2M in cash, expected to last until Q1 2025.
March 25, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics beats EPS estimates and reports a significant cash position, indicating improved financial health and operational runway.
Beating EPS estimates typically signals stronger financial performance than anticipated, which can positively influence investor sentiment. The reported cash position provides the company with a substantial runway, reducing immediate financial risk and potentially attracting more investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100